SELLAS Life Sciences (SLS) Common Equity (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Common Equity for 9 consecutive years, with $15.9 million as the latest value for Q3 2024.
- Quarterly Common Equity rose 515.26% to $15.9 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $15.9 million through Sep 2024, up 515.26% year-over-year, with the annual reading at -$8.0 million for FY2023, 264.42% down from the prior year.
- Common Equity for Q3 2024 was $15.9 million at SELLAS Life Sciences, up from $2.9 million in the prior quarter.
- The five-year high for Common Equity was $33.4 million in Q2 2021, with the low at -$8.0 million in Q4 2023.
- Average Common Equity over 5 years is $12.2 million, with a median of $9.7 million recorded in 2024.
- The sharpest move saw Common Equity skyrocketed 783.29% in 2021, then tumbled 264.42% in 2023.
- Over 5 years, Common Equity stood at $28.0 million in 2020, then dropped by 27.23% to $20.3 million in 2021, then plummeted by 76.16% to $4.9 million in 2022, then crashed by 264.42% to -$8.0 million in 2023, then skyrocketed by 299.25% to $15.9 million in 2024.
- According to Business Quant data, Common Equity over the past three periods came in at $15.9 million, $2.9 million, and $9.7 million for Q3 2024, Q2 2024, and Q1 2024 respectively.